Moderator: Larus S. Gudmundsson (he/him/his) – University of Iceland

Moderator: Almut G. Winterstein, PhD, FISPE – University of Florida, Pharmaceutical Outcomes & Policy, Center for Drug Evaluation & Safety

Speaker: Martin Ingi I. Sigurdsson, MD, PhD (he/him/his) – Faculty of Medicine, University of Iceland, Reykjavík, Iceland; Department of Anesthesiology and Critical Care Medicine, Landspitali–The National University Hospital, Reykjavík, Iceland.

Speaker: Guðrún Aspelund (she/her/hers) – Directorate of Health Iceland

Speaker: Menno van der Elst (he/him/his) – Dutch Medicines ‎Evaluation Board‎

Moderator: Helga Gardarsdottir, PharmD, PhD, – Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht University

Moderator: Tobias Gerhard, PhD, FISPE (he/him/his) – Center for Pharmacoepidemiology and Treatment Science, Rutgers University

Speaker: Anne M. Butler, PhD, MS (she/her/hers) – Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine

Speaker: Michael Andrew Webster-Clark, PharmD, PhD – McGill University, Department of Epidemiology, Biostatistics, and Occupational Health

Speaker: Morten Andersen, MD, PhD – Pharmacovigilance Research Center, Department of Drug Design and Pharmacology, University of Copenhagen

Moderator: Andrew Bate – GlaxoSmithKline

Moderator: Susana Perez-Gutthann, MD, MPH, PhD, FISPE, FRCP – Research Triangle Institute

Speaker: Alison Cave, PhD – Medicines and Healthcare products Regulatory Agency (UK)

Speaker: Robert W. Platt, PhD (he/him/his) – Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montreal, QC, Canada

Speaker: Jamie Geier (she/her/hers) – Novartis Pharma AG